Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2024 | |
|---|---|
| Revenue | $0 |
| Cost of revenue | $0 |
| Gross profit | $0 |
| Gross margin | — |
| R&D | $77.1M |
| Operating income | −$111.6M |
| EBITDA | −$111.6M |
| Net income | −$94.3M |
| Net margin | — |
| EPS (diluted) | -1.68 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CATB.
No tracked institution reports a position in CATB as of their last filing.
No one on the platform has traded CATB yet.
| $226M |
| — |
| INZYInozyme Pharma, Inc. | $4.00 | +0.25% | $258M | — |
| MACKMerrimack Pharmaceuticals, Inc. | $15.14 | +0.10% | $224M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.